Clinical Trial: A Long-Term Study of Bivamelagon in Participants With Hypothalamic Obesity (HO)

U.S., Sept. 6 -- ClinicalTrials.gov registry received information related to the study (NCT07156578) titled 'A Long-Term Study of Bivamelagon in Participants With Hypothalamic Obesity (HO)' on Aug. 25.

Brief Summary: This is a long-term, open-label extension study of bivamelagon in participants with Hypothalamic Obesity (HO) who have transitioned from the index study, LG-MCCL005. The study will last up to 2 years.

Study Start Date: Nov. 03

Study Type: INTERVENTIONAL

Condition: Hypothalamic Obesity

Intervention: DRUG: Bivamelagon

daily dose of oral bivamelagon

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Rhythm Pharmaceuticals, Inc.

Disclaimer: Curated by HT Syndication....